45 CFR § 180 compliance
B · 85
This hospital published most of what § 180 requires.
●Machine-readable file published: assessment threshold met
●Gross / standard charges: assessment threshold met
●Discounted cash price: assessment threshold met
●Payer-specific negotiated rates: assessment threshold met
○Min / max negotiated charges: below assessment threshold
●Free, public, no login required: assessment threshold met
Procedures listed
2,536
Insurances with rates
13
CPT / HCPCS codes
2,423
Most expensive procedures (gross)
J9347
$170,526
Tremelimumab-Actl 300 Mg/15 Ml
Gross
$175,800
J9347
$170,526
Tremelimumab-Actl 300 Mg/15 Ml
Gross
$175,800
J2350
$67,003
Ocrelizumab 300 Mg/10 Ml
Gross
$69,075
J2350
$67,003
Ocrelizumab 300 Mg/10 Ml
Gross
$69,075
J9334
$56,049
Efgart-Hyalu-QVFC 1008Mg/5.6Ml
Gross
$57,782
J9334
$56,049
Efgart-Hyalu-QVFC 1008Mg/5.6Ml
Gross
$57,782
J9272
$51,232
Dostarlimab-Gxly 500 Mg/10 Ml
Gross
$52,816
J9272
$51,232
Dostarlimab-Gxly 500 Mg/10 Ml
Gross
$52,816
J9022
$47,975
Atezolizumab 1200 Mg/20 Ml Vl
Gross
$49,458
J9022
$47,975
Atezolizumab 1200 Mg/20 Ml Vl
Gross
$49,458
J9203
$43,489
Gemtuzumab Ozogamicin 4.5 Mg
Gross
$44,834
J9203
$43,489
Gemtuzumab Ozogamicin 4.5 Mg
Gross
$44,834
J9042
$41,149
Brentuximab Vedotin 50 MG Vial
Gross
$42,421
J9042
$41,149
Brentuximab Vedotin 50 MG Vial
Gross
$42,421
J3357
$40,549
Ustekinumab 45 MG/0.5 ML Syr
Gross
$41,802
J3357
$40,549
Ustekinumab 45 MG/0.5 ML Syr
Gross
$41,802
J9043
$40,505
Cabazitaxel 60 MG/1.5 ML Vial
Gross
$41,757
J9043
$40,505
Cabazitaxel 60 MG/1.5 ML Vial
Gross
$41,757
J9144
$33,641
Daratumumab Hyaluronida 1800Mg
Gross
$34,681
J9144
$33,641
Daratumumab Hyaluronida 1800Mg
Gross
$34,681
J1930
$33,227
Lanreotide Acet 120MG/0.5ML Sy
Gross
$34,254
J1930
$33,227
Lanreotide Acet 120MG/0.5ML Sy
Gross
$34,254
J3380
$30,938
Vedolizumab 300 MG Vial
Gross
$31,894
J3380
$30,938
Vedolizumab 300 MG Vial
Gross
$31,894
J3101
$30,637
Tenecteplase 50 Mg/10 Ml Syrng
Gross
$31,584
J3101
$30,637
Tenecteplase 50 Mg/10 Ml Syrng
Gross
$31,584
J2323
$29,609
Natalizumab 300 MG/15 ML Vial
Gross
$30,524
J2323
$29,609
Natalizumab 300 MG/15 ML Vial
Gross
$30,524
J9063
$28,602
Mirvetuximab Soravtansine-Gynx
Gross
$29,486
J9063
$28,602
Mirvetuximab Soravtansine-Gynx
Gross
$29,486
J9228
$28,517
Ipilimumab 5 MG/ML 10 ML Vial
Gross
$29,399
J9228
$28,517
Ipilimumab 5 MG/ML 10 ML Vial
Gross
$29,399
J9299
$28,133
Nivolumab 240 Mg/24 Ml Vial
Gross
$29,002
J9299
$28,133
Nivolumab 240 Mg/24 Ml Vial
Gross
$29,002
J9332
$26,540
Efgartigimod Alfa-Fcab 400 Mg
Gross
$27,360
J9332
$26,540
Efgartigimod Alfa-Fcab 400 Mg
Gross
$27,360
J9306
$25,946
Pertuzumab 420 MG/14 ML Vial
Gross
$26,748
J9306
$25,946
Pertuzumab 420 MG/14 ML Vial
Gross
$26,748
J0517
$21,969
Benralizumab 30 mg/ml Syringe
Gross
$22,647
J0517
$21,969
Benralizumab 30 mg/ml Syringe
Gross
$22,647
J0717
$21,524
Certolizumab Pegol 400 Mg Kit
Gross
$22,189
J0717
$21,524
Certolizumab Pegol 400 Mg Kit
Gross
$22,189
J9271
$19,992
Pembrolizumab 100 MG/4 ML Vial
Gross
$20,610
J9271
$19,992
Pembrolizumab 100 MG/4 ML Vial
Gross
$20,610
J2353
$18,467
Octreotide (Depot) 20 MG Syr
Gross
$19,038
J2353
$18,467
Octreotide (Depot) 20 MG Syr
Gross
$19,038
J9173
$18,115
Durvalumab 500 Mg/10 Ml Vial
Gross
$18,675
J9173
$18,115
Durvalumab 500 Mg/10 Ml Vial
Gross
$18,675
Q5120
$17,279
Pegfilgrastim-Bmez 6 Mg/0.6 Ml
Gross
$17,813
Q5120
$17,279
Pegfilgrastim-Bmez 6 Mg/0.6 Ml
Gross
$17,813
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| J9347 | Tremelimumab-Actl 300 Mg/15 Ml | $175,800 | $170,526 | — | — | 6 |
| J9347 | Tremelimumab-Actl 300 Mg/15 Ml | $175,800 | $170,526 | — | — | 6 |
| J2350 | Ocrelizumab 300 Mg/10 Ml | $69,075 | $67,003 | — | — | 6 |
| J2350 | Ocrelizumab 300 Mg/10 Ml | $69,075 | $67,003 | — | — | 7 |
| J9334 | Efgart-Hyalu-QVFC 1008Mg/5.6Ml | $57,782 | $56,049 | — | — | 6 |
| J9334 | Efgart-Hyalu-QVFC 1008Mg/5.6Ml | $57,782 | $56,049 | — | — | 6 |
| J9272 | Dostarlimab-Gxly 500 Mg/10 Ml | $52,816 | $51,232 | — | — | 6 |
| J9272 | Dostarlimab-Gxly 500 Mg/10 Ml | $52,816 | $51,232 | — | — | 6 |
| J9022 | Atezolizumab 1200 Mg/20 Ml Vl | $49,458 | $47,975 | — | — | 6 |
| J9022 | Atezolizumab 1200 Mg/20 Ml Vl | $49,458 | $47,975 | — | — | 6 |
| J9203 | Gemtuzumab Ozogamicin 4.5 Mg | $44,834 | $43,489 | — | — | 6 |
| J9203 | Gemtuzumab Ozogamicin 4.5 Mg | $44,834 | $43,489 | — | — | 6 |
| J9042 | Brentuximab Vedotin 50 MG Vial | $42,421 | $41,149 | — | — | 6 |
| J9042 | Brentuximab Vedotin 50 MG Vial | $42,421 | $41,149 | — | — | 6 |
| J3357 | Ustekinumab 45 MG/0.5 ML Syr | $41,802 | $40,549 | — | — | 6 |
| J3357 | Ustekinumab 45 MG/0.5 ML Syr | $41,802 | $40,549 | — | — | 6 |
| J9043 | Cabazitaxel 60 MG/1.5 ML Vial | $41,757 | $40,505 | — | — | 6 |
| J9043 | Cabazitaxel 60 MG/1.5 ML Vial | $41,757 | $40,505 | — | — | 6 |
| J9144 | Daratumumab Hyaluronida 1800Mg | $34,681 | $33,641 | — | — | 8 |
| J9144 | Daratumumab Hyaluronida 1800Mg | $34,681 | $33,641 | — | — | 6 |
| J1930 | Lanreotide Acet 120MG/0.5ML Sy | $34,254 | $33,227 | — | — | 6 |
| J1930 | Lanreotide Acet 120MG/0.5ML Sy | $34,254 | $33,227 | — | — | 6 |
| J3380 | Vedolizumab 300 MG Vial | $31,894 | $30,938 | — | — | 6 |
| J3380 | Vedolizumab 300 MG Vial | $31,894 | $30,938 | — | — | 6 |
| J3101 | Tenecteplase 50 Mg/10 Ml Syrng | $31,584 | $30,637 | — | — | 8 |
| J3101 | Tenecteplase 50 Mg/10 Ml Syrng | $31,584 | $30,637 | — | — | 6 |
| J2323 | Natalizumab 300 MG/15 ML Vial | $30,524 | $29,609 | — | — | 6 |
| J2323 | Natalizumab 300 MG/15 ML Vial | $30,524 | $29,609 | — | — | 6 |
| J9063 | Mirvetuximab Soravtansine-Gynx | $29,486 | $28,602 | — | — | 6 |
| J9063 | Mirvetuximab Soravtansine-Gynx | $29,486 | $28,602 | — | — | 6 |
| J9228 | Ipilimumab 5 MG/ML 10 ML Vial | $29,399 | $28,517 | — | — | 6 |
| J9228 | Ipilimumab 5 MG/ML 10 ML Vial | $29,399 | $28,517 | — | — | 6 |
| J9299 | Nivolumab 240 Mg/24 Ml Vial | $29,002 | $28,133 | — | — | 6 |
| J9299 | Nivolumab 240 Mg/24 Ml Vial | $29,002 | $28,133 | — | — | 6 |
| J9332 | Efgartigimod Alfa-Fcab 400 Mg | $27,360 | $26,540 | — | — | 6 |
| J9332 | Efgartigimod Alfa-Fcab 400 Mg | $27,360 | $26,540 | — | — | 6 |
| J9306 | Pertuzumab 420 MG/14 ML Vial | $26,748 | $25,946 | — | — | 8 |
| J9306 | Pertuzumab 420 MG/14 ML Vial | $26,748 | $25,946 | — | — | 6 |
| J0517 | Benralizumab 30 mg/ml Syringe | $22,647 | $21,969 | — | — | 6 |
| J0517 | Benralizumab 30 mg/ml Syringe | $22,647 | $21,969 | — | — | 6 |
| J0717 | Certolizumab Pegol 400 Mg Kit | $22,189 | $21,524 | — | — | 6 |
| J0717 | Certolizumab Pegol 400 Mg Kit | $22,189 | $21,524 | — | — | 6 |
| J9271 | Pembrolizumab 100 MG/4 ML Vial | $20,610 | $19,992 | — | — | 6 |
| J9271 | Pembrolizumab 100 MG/4 ML Vial | $20,610 | $19,992 | — | — | 6 |
| J2353 | Octreotide (Depot) 20 MG Syr | $19,038 | $18,467 | — | — | 8 |
| J2353 | Octreotide (Depot) 20 MG Syr | $19,038 | $18,467 | — | — | 6 |
| J9173 | Durvalumab 500 Mg/10 Ml Vial | $18,675 | $18,115 | — | — | 6 |
| J9173 | Durvalumab 500 Mg/10 Ml Vial | $18,675 | $18,115 | — | — | 6 |
| Q5120 | Pegfilgrastim-Bmez 6 Mg/0.6 Ml | $17,813 | $17,279 | — | — | 6 |
| Q5120 | Pegfilgrastim-Bmez 6 Mg/0.6 Ml | $17,813 | $17,279 | — | — | 6 |
Showing top 50 of 2,536 priced procedures, sorted by gross charge.
Data straight from this hospital's federally-mandated machine-readable file (45 CFR § 180). The compliance grade reflects how completely the hospital published the six required data elements, not the quality of care.